BioInvent International AB (publ) (BINV.ST)
SEK 24.75
(-6.6%)
SEK 24.75
(-6.6%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -312.7 Million SEK | -1204.23% |
| 2022 | -27.12 Million SEK | 89.7% |
| 2021 | -263.31 Million SEK | -311.48% |
| 2020 | -63.99 Million SEK | 49.43% |
| 2019 | -126.53 Million SEK | -7.15% |
| 2018 | -118.09 Million SEK | -18.82% |
| 2017 | -97.64 Million SEK | -60.09% |
| 2016 | -61.59 Million SEK | 33.84% |
| 2015 | -93.37 Million SEK | -80.65% |
| 2014 | -51.94 Million SEK | -243.02% |
| 2013 | -15.14 Million SEK | 91.67% |
| 2012 | -182.35 Million SEK | -199.94% |
| 2011 | -60.74 Million SEK | 48.43% |
| 2010 | -117.47 Million SEK | 28.96% |
| 2009 | -165.54 Million SEK | -693.89% |
| 2008 | 27.84 Million SEK | -22.2% |
| 2007 | -4.67 Million SEK | 138.32% |
| 2006 | -93.4 Million SEK | 21.87% |
| 2005 | -119.54 Million SEK | 11.96% |
| 2004 | -71.54 Million SEK | 8.61% |
| 2003 | -148.59 Million SEK | -9.27% |
| 2002 | -135.99 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -92.38 Million SEK | 28.67% |
| 2024 Q1 | -85.03 Million SEK | 8.0% |
| 2024 Q2 | -143.58 Million SEK | -68.74% |
| 2023 Q3 | -87.64 Million SEK | 13.28% |
| 2023 Q2 | -101.06 Million SEK | -19.89% |
| 2023 Q1 | -84.29 Million SEK | -27.38% |
| 2023 FY | - SEK | -1204.23% |
| 2023 Q4 | -106.85 Million SEK | -21.92% |
| 2022 Q2 | 167.7 Million SEK | 356.61% |
| 2022 FY | - SEK | 89.7% |
| 2022 Q4 | -66.17 Million SEK | 6.52% |
| 2022 Q3 | -70.79 Million SEK | -142.21% |
| 2022 Q1 | -65.35 Million SEK | 12.56% |
| 2021 Q4 | -74.74 Million SEK | -28.04% |
| 2021 Q2 | -53.35 Million SEK | 30.41% |
| 2021 FY | - SEK | -311.48% |
| 2021 Q3 | -58.37 Million SEK | -9.41% |
| 2021 Q1 | -76.66 Million SEK | -339.64% |
| 2020 Q1 | -30.47 Million SEK | 20.04% |
| 2020 Q2 | -35.86 Million SEK | -17.69% |
| 2020 Q4 | 31.99 Million SEK | 207.8% |
| 2020 Q3 | -29.67 Million SEK | 17.25% |
| 2020 FY | - SEK | 49.43% |
| 2019 Q1 | -24.83 Million SEK | 20.3% |
| 2019 FY | - SEK | -7.15% |
| 2019 Q3 | -33.95 Million SEK | -14.53% |
| 2019 Q4 | -38.11 Million SEK | -12.25% |
| 2019 Q2 | -29.64 Million SEK | -19.38% |
| 2018 Q1 | -24.17 Million SEK | 24.6% |
| 2018 Q2 | -42.28 Million SEK | -74.93% |
| 2018 FY | - SEK | -18.82% |
| 2018 Q3 | -21.06 Million SEK | 50.18% |
| 2018 Q4 | -31.15 Million SEK | -47.87% |
| 2017 Q4 | -32.05 Million SEK | -55.06% |
| 2017 Q3 | -20.67 Million SEK | 10.3% |
| 2017 Q1 | -21.85 Million SEK | -272.68% |
| 2017 FY | - SEK | -60.09% |
| 2017 Q2 | -23.04 Million SEK | -5.49% |
| 2016 FY | - SEK | 33.84% |
| 2016 Q3 | -28.42 Million SEK | -3.62% |
| 2016 Q2 | -27.43 Million SEK | -8983.44% |
| 2016 Q1 | -302 Thousand SEK | 98.79% |
| 2016 Q4 | -5.86 Million SEK | 79.37% |
| 2015 Q4 | -25.02 Million SEK | -13.14% |
| 2015 FY | - SEK | -80.65% |
| 2015 Q3 | -22.12 Million SEK | 11.31% |
| 2015 Q2 | -24.94 Million SEK | -14.2% |
| 2015 Q1 | -21.84 Million SEK | 12.21% |
| 2014 Q2 | 3.58 Million SEK | 118.01% |
| 2014 Q4 | -24.87 Million SEK | -117.01% |
| 2014 Q1 | -19.9 Million SEK | -189.45% |
| 2014 FY | - SEK | -243.02% |
| 2014 Q3 | -11.46 Million SEK | -419.87% |
| 2013 Q4 | 22.25 Million SEK | 256.54% |
| 2013 Q2 | -9.49 Million SEK | 29.36% |
| 2013 FY | - SEK | 91.67% |
| 2013 Q1 | -13.44 Million SEK | 41.9% |
| 2013 Q3 | -14.21 Million SEK | -49.72% |
| 2012 Q1 | -36.19 Million SEK | 39.02% |
| 2012 Q3 | -36.38 Million SEK | 60.8% |
| 2012 Q4 | -23.13 Million SEK | 36.42% |
| 2012 FY | - SEK | -199.94% |
| 2012 Q2 | -92.8 Million SEK | -156.43% |
| 2011 Q4 | -59.35 Million SEK | -65.86% |
| 2011 Q3 | -35.78 Million SEK | -16.77% |
| 2011 Q2 | -30.64 Million SEK | -150.63% |
| 2011 Q1 | 60.53 Million SEK | 252.83% |
| 2011 FY | - SEK | 48.43% |
| 2010 FY | - SEK | 28.96% |
| 2010 Q4 | -39.6 Million SEK | -74.63% |
| 2010 Q3 | -22.68 Million SEK | -11.65% |
| 2010 Q2 | -20.31 Million SEK | 41.75% |
| 2010 Q1 | -34.87 Million SEK | 13.44% |
| 2009 Q3 | -40.08 Million SEK | 22.34% |
| 2009 Q2 | -51.61 Million SEK | -54.55% |
| 2009 FY | - SEK | -693.89% |
| 2009 Q4 | -40.29 Million SEK | -0.52% |
| 2009 Q1 | -33.39 Million SEK | 0.0% |
| 2008 FY | - SEK | -22.2% |
| 2007 FY | - SEK | 138.32% |
| 2006 FY | - SEK | 21.87% |
| 2005 FY | - SEK | 11.96% |
| 2004 FY | - SEK | 8.61% |
| 2003 FY | - SEK | -9.27% |
| 2002 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | -1298.323% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 1.499% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | -10.876% |
| Xintela AB (publ) | -53.47 Million SEK | -484.816% |
| Active Biotech AB (publ) | -43.88 Million SEK | -612.528% |
| Amniotics AB (publ) | -27.14 Million SEK | -1052.072% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -2099.529% |
| BioArctic AB (publ) | 275.38 Million SEK | 213.552% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 14.98% |
| Camurus AB (publ) | 562.54 Million SEK | 155.588% |
| Cantargia AB (publ) | -284.31 Million SEK | -9.986% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -1497.155% |
| CombiGene AB (publ) | -35.33 Million SEK | -784.952% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -122.013% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -1730.354% |
| Genovis AB (publ.) | 64.57 Million SEK | 584.276% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -172.139% |
| Mendus AB (publ) | -97.84 Million SEK | -219.591% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -744.606% |
| Intervacc AB (publ) | -68.98 Million SEK | -353.33% |
| Kancera AB (publ) | -61.88 Million SEK | -405.271% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -1067.558% |
| LIDDS AB (publ) | -39.67 Million SEK | -688.271% |
| Lipum AB (publ) | -37.11 Million SEK | -742.445% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -2483.501% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 1095.755% |
| NextCell Pharma AB | -40.98 Million SEK | -662.976% |
| OncoZenge AB (publ) | 7.26 Million SEK | 4403.702% |
| Saniona AB (publ) | -69.69 Million SEK | -348.679% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | -84.146% |
| Ziccum AB (publ) | -20.34 Million SEK | -1437.248% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 15635450.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | -31.603% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -14933.99% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -2228.248% |
| Corline Biomedical AB | -1.69 Million SEK | -18392.431% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | -80.418% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -470.571% |
| Aptahem AB (publ) | -10 Million SEK | -3024.187% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 2807.654% |
| Fluicell AB (publ) | -25.91 Million SEK | -1106.711% |
| Biovica International AB (publ) | -119.5 Million SEK | -161.666% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -640.591% |
| AcouSort AB (publ) | -16.7 Million SEK | -1772.161% |
| Abliva AB (publ) | -93.6 Million SEK | -234.06% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 2.003% |
| 2cureX AB (publ) | -35.13 Million SEK | -789.99% |
| I-Tech AB | 30.34 Million SEK | 1130.506% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 56.237% |
| Cyxone AB (publ) | -20.41 Million SEK | -1431.826% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -205.22% |
| Biosergen AB | 228 Thousand SEK | 137252.193% |
| Nanologica AB (publ) | -62.11 Million SEK | -403.4% |
| SynAct Pharma AB | -222.7 Million SEK | -40.416% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -612.95% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 101164.597% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 744658.204% |
| Oncopeptides AB (publ) | -231.62 Million SEK | -35.007% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -3448.457% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -188.055% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -2626.541% |